Corcept Therapeutics

$27.97 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Stock Analysis

last close $27.97
1-mo return 8%
3-mo return 61.4%
avg daily vol. 648.42T
52-week high 29.93
52-week low 15.83
market cap. $3.1B
forward pe 27.9
annual div. -
roe 23.4%
ltg forecast -
dividend yield -
annual rev. $392M
inst own. 77.1%
baraka

Subscribe now for daily local and international financial news

Subscribe